JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $86
Author: Benzinga Newsdesk | August 11, 2025 07:08am
JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $90 to $86.